Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

559 ARTÍCULOS , VIENDO DEL 166 AL 180

Therapeutic Candidates for Alzheimer's Disease: Saponins

Zhang R, Zeng M, Zhang X, Zheng Y, Lv N, Wang L, Gan J, Li Y, Jiang X, Yang L.

Int J Mol Sci. 2023 Jun 22;24(13):10505. doi: 10.3390/ijms241310505.

Vitamin E and Its Molecular Effects in Experimental Models of Neurodegenerative Diseases

da Cunha Germano BC, de Morais LCC, Idalina Neta F, Fernandes ACL, Pinheiro FI, do Rego ACM, Araújo Filho I, de Azevedo EP, de Paiva Cavalcanti JRL, Guzen FP, Cobucci RN.

Int J Mol Sci. 2023 Jul 7;24(13):11191. doi: 10.3390/ijms241311191.

The potential of psychedelics for the treatment of Alzheimer's disease and related dementias

Winkelman MJ, Szabo A, Frecska E.

Eur Neuropsychopharmacol. 2023 Nov;76:3-16. doi: 10.1016/j.euroneuro.2023.07.003. Epub 2023 Jul 12.

Ushering in a New Era of Alzheimer Disease Therapy

Widera EW, Brangman SA, Chin NA.

JAMA. 2023 Aug 8;330(6):503-504. doi: 10.1001/jama.2023.11701.

Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease

Rabinovici GD, La Joie R.

JAMA. 2023 Aug 8;330(6):507-509. doi: 10.1001/jama.2023.11703.

Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy

Rosenthal MB.

JAMA. 2023 Aug 8;330(6):505-506. doi: 10.1001/jama.2023.11702.

Exploring New Vista for Alzheimer's Disease Drug Targets (Part II)

Bolinger AA, Zhou J.

Curr Top Med Chem. 2023;23(13):1211-1213. doi: 10.2174/156802662313230626121232.

Targeted Regulation of Intracellular Signal Transduction: A New Paradigm for Stimulation of Neurogenesis in Alzheimer's Disease

Zyuz'kov G.

Curr Drug Targets. 2023;24(10):777-780. doi: 10.2174/1389450124666230719104808.

Expression and function of estrogen receptors and estrogen-related receptors in the brain and their association with Alzheimer's disease

Sato K, Takayama KI, Inoue S.

Front Endocrinol (Lausanne). 2023 Jul 4;14:1220150. doi: 10.3389/fendo.2023.1220150. eCollection 2023.

Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer's Disease

Leisher S, Bohorquez A, Gay M, Garcia V, Jones R, Baldaranov D, Rafii MS.

CNS Drugs. 2023 Aug;37(8):671-677. doi: 10.1007/s40263-023-01021-8. Epub 2023 Jul 20.

The aquaporin-4 water channel and updates on its potential as a drug target for Alzheimer's disease

Silverglate B, Gao X, Lee HP, Maliha P, Grossberg GT.

Expert Opin Ther Targets. 2023 Jul-Dec;27(7):523-530. doi: 10.1080/14728222.2023.2240017. Epub 2023 Jul 27.

Patent analysis of novel therapeutic approaches for treating Alzheimer's disease 2018-2023

Saleem F, Naz F, Khan KM.

Pharm Pat Anal. 2023 May;12(3):91-94. doi: 10.4155/ppa-2023-0020. Epub 2023 Jul 21.

Nanowired Delivery of Cerebrolysin Together with Antibodies to Amyloid Beta Peptide, Phosphorylated Tau, and Tumor Necrosis Factor Alpha Induces Superior Neuroprotection in Alzheimer's Disease Brain Pathology Exacerbated by Sleep Deprivation

Sharma A, Feng L, Muresanu DF, Tian ZR, Lafuente JV, Buzoianu AD, Nozari A, Bryukhovetskiy I, Manzhulo I, Wiklund L, Sharma HS.

Adv Neurobiol. 2023;32:3-53. doi: 10.1007/978-3-031-32997-5_1.

Effect of internet-based vs. in-person multimodal interventions on patients with mild to moderate Alzheimer's disease: a randomized, cross-over, open-label trial

Jung YH, Park SC, Lee JH, Kim MJ, Lee S, Chung SJ, Moon JY, Choi YH, Ju J, Han HJ, Lee SY.

Front Public Health. 2023 Jul 7;11:1203201. doi: 10.3389/fpubh.2023.1203201. eCollection 2023.

Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update

Yadollahikhales G, Rojas JC.

Neurotherapeutics. 2023 Jul;20(4):914-931. doi: 10.1007/s13311-023-01405-0. Epub 2023 Jul 25.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias